MX384259B - Composiciones y metodos para tratamiento de crecimiento celular anormal. - Google Patents

Composiciones y metodos para tratamiento de crecimiento celular anormal.

Info

Publication number
MX384259B
MX384259B MX2016009056A MX2016009056A MX384259B MX 384259 B MX384259 B MX 384259B MX 2016009056 A MX2016009056 A MX 2016009056A MX 2016009056 A MX2016009056 A MX 2016009056A MX 384259 B MX384259 B MX 384259B
Authority
MX
Mexico
Prior art keywords
treatment
methods
cell growth
abnormal cell
compositions
Prior art date
Application number
MX2016009056A
Other languages
English (en)
Other versions
MX2016009056A (es
Inventor
Mahesh Padval
Paul Okwabi Nkansah
Original Assignee
Verastem Inc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc, Pfizer filed Critical Verastem Inc
Publication of MX2016009056A publication Critical patent/MX2016009056A/es
Publication of MX384259B publication Critical patent/MX384259B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invención se refiere a formas de dosificación oral y métodos que son útiles en el tratamiento de crecimiento celular anormal, tal como cáncer, en mamíferos, especialmente humanos.
MX2016009056A 2014-01-09 2015-01-09 Composiciones y metodos para tratamiento de crecimiento celular anormal. MX384259B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
PCT/US2015/010810 WO2015106096A1 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
MX2016009056A MX2016009056A (es) 2017-01-23
MX384259B true MX384259B (es) 2025-03-14

Family

ID=52434976

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009056A MX384259B (es) 2014-01-09 2015-01-09 Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2021008225A MX2021008225A (es) 2014-01-09 2016-07-08 Composiciones y metodos para tratamiento de crecimiento celular anormal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008225A MX2021008225A (es) 2014-01-09 2016-07-08 Composiciones y metodos para tratamiento de crecimiento celular anormal.

Country Status (15)

Country Link
US (3) US20150190346A1 (es)
EP (2) EP3091981B1 (es)
JP (5) JP6647204B2 (es)
KR (3) KR20240159639A (es)
CN (3) CN115708827A (es)
AU (4) AU2015204597B2 (es)
BR (1) BR112016016021B1 (es)
CA (1) CA2936283C (es)
DK (1) DK3091981T3 (es)
ES (1) ES2870562T3 (es)
IL (2) IL246667B (es)
MX (2) MX384259B (es)
NZ (2) NZ721934A (es)
SG (2) SG10201805890QA (es)
WO (1) WO2015106096A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019218958A1 (zh) * 2018-05-15 2019-11-21 江苏豪森药业集团有限公司 包含小分子egfr抑制剂的药物组合物及其制备方法
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
US20230201185A1 (en) * 2020-03-27 2023-06-29 Pfizer Inc. Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
WO2005011634A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
ES2593486T3 (es) 2007-04-18 2016-12-09 Pfizer Products Inc. Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
CN102231990B (zh) * 2008-08-13 2013-09-25 沃泰克斯药物股份有限公司 N-[2，4-双(1，1-二甲基乙基)-5-羟基苯基]-1，4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2012027247A2 (en) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
CN103491964A (zh) * 2011-03-08 2014-01-01 扎里卡斯药品有限公司 固体分散体制剂及其使用方法
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
ES2945387T3 (es) * 2014-02-07 2023-06-30 Verastem Inc Procedimientos y composiciones para tratar el crecimiento celular anormal
CA2991044C (en) * 2015-06-29 2024-11-19 Verastem, Inc. THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE

Also Published As

Publication number Publication date
JP2025084892A (ja) 2025-06-03
IL246667B (en) 2022-05-01
CN106102744A (zh) 2016-11-09
US20200038331A1 (en) 2020-02-06
JP2022001587A (ja) 2022-01-06
AU2020210153A1 (en) 2020-08-13
SG10201805890QA (en) 2018-08-30
SG11201605588YA (en) 2016-08-30
DK3091981T3 (da) 2021-05-31
WO2015106096A1 (en) 2015-07-16
EP3091981A1 (en) 2016-11-16
NZ721934A (en) 2022-04-29
KR102444494B1 (ko) 2022-09-20
ES2870562T3 (es) 2021-10-27
AU2022256144A1 (en) 2022-11-24
MX2016009056A (es) 2017-01-23
KR20220130251A (ko) 2022-09-26
AU2015204597A1 (en) 2016-07-21
BR112016016021A2 (pt) 2017-09-19
IL246667A0 (en) 2016-08-31
AU2020210153B2 (en) 2022-07-21
US20150190346A1 (en) 2015-07-09
BR112016016021A8 (pt) 2018-04-17
NZ760233A (en) 2022-04-29
IL292054A (en) 2022-06-01
AU2022256144B2 (en) 2025-04-03
CA2936283A1 (en) 2015-07-16
EP3900726A1 (en) 2021-10-27
JP2023065568A (ja) 2023-05-12
MX2021008225A (es) 2021-08-11
AU2025204843A1 (en) 2025-07-17
CA2936283C (en) 2023-02-28
EP3091981B1 (en) 2021-03-10
BR112016016021B1 (pt) 2023-01-10
KR20240159639A (ko) 2024-11-05
KR20160104725A (ko) 2016-09-05
US20230104303A1 (en) 2023-04-06
JP2020007355A (ja) 2020-01-16
AU2015204597B2 (en) 2020-04-30
CN115708827A (zh) 2023-02-24
CN119868364A (zh) 2025-04-25
JP2017502062A (ja) 2017-01-19
JP6647204B2 (ja) 2020-02-14

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
UY37018A (es) Inhibidores bicíclicos de pad4
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
MX378145B (es) Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX386859B (es) Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
PH12017501864A1 (en) Compositions and methods for treating autism
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX384259B (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,